Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Fiche du document

Auteurs

Discipline

Psychologie

Type de document

Articles

Périmètre

Publications

Langue

Anglais

Identifiants

doi: 10.3324/haematol.2017.179150
issn: 0390-6078

Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3324/haematol.2017.179150

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29097496

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1592-8721

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_12A8F7D8B6266

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Biomarkers; Biopsy; Combined Modality Therapy; Histiocytic Sarcoma/diagnosis; Histiocytic Sarcoma/drug therapy; Histiocytic Sarcoma/metabolism; Humans; Imatinib Mesylate/administration & dosage; Immunohistochemistry; Immunophenotyping; Male; Molecular Targeted Therapy; Positron Emission Tomography Computed Tomography; Pyridones/administration & dosage; Pyrimidinones/administration & dosage; Retreatment; Symptom Assessment; Treatment Outcome

Sujets proches En

Therapy

Citer ce document

S. Voruz et al., « Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. », Serveur académique Lausannois, ID : 10.3324/haematol.2017.179150

Partage / Export

export

document thumbnail